Cargando…

Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance

Radiotherapy plays a central role in the treatment of cancer patients. Over the past decades, remarkable technological progress has been made in the field of conventional radiotherapy. In addition, the use of charged particles (e.g., protons and carbon ions) makes it possible to further improve dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Konings, Katrien, Vandevoorde, Charlot, Baselet, Bjorn, Baatout, Sarah, Moreels, Marjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033551/
https://www.ncbi.nlm.nih.gov/pubmed/32117774
http://dx.doi.org/10.3389/fonc.2020.00128
_version_ 1783499694093107200
author Konings, Katrien
Vandevoorde, Charlot
Baselet, Bjorn
Baatout, Sarah
Moreels, Marjan
author_facet Konings, Katrien
Vandevoorde, Charlot
Baselet, Bjorn
Baatout, Sarah
Moreels, Marjan
author_sort Konings, Katrien
collection PubMed
description Radiotherapy plays a central role in the treatment of cancer patients. Over the past decades, remarkable technological progress has been made in the field of conventional radiotherapy. In addition, the use of charged particles (e.g., protons and carbon ions) makes it possible to further improve dose deposition to the tumor, while sparing the surrounding healthy tissues. Despite these improvements, radioresistance and tumor recurrence are still observed. Although the mechanisms underlying resistance to conventional radiotherapy are well-studied, scientific evidence on the impact of charged particle therapy on cancer cell radioresistance is restricted. The purpose of this review is to discuss the potential role that charged particles could play to overcome radioresistance. This review will focus on hypoxia, cancer stem cells, and specific signaling pathways of EGFR, NFκB, and Hedgehog as well as DNA damage signaling involving PARP, as mechanisms of radioresistance for which pharmacological targets have been identified. Finally, new lines of future research will be proposed, with a focus on novel molecular inhibitors that could be used in combination with charged particle therapy as a novel treatment option for radioresistant tumors.
format Online
Article
Text
id pubmed-7033551
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70335512020-02-28 Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance Konings, Katrien Vandevoorde, Charlot Baselet, Bjorn Baatout, Sarah Moreels, Marjan Front Oncol Oncology Radiotherapy plays a central role in the treatment of cancer patients. Over the past decades, remarkable technological progress has been made in the field of conventional radiotherapy. In addition, the use of charged particles (e.g., protons and carbon ions) makes it possible to further improve dose deposition to the tumor, while sparing the surrounding healthy tissues. Despite these improvements, radioresistance and tumor recurrence are still observed. Although the mechanisms underlying resistance to conventional radiotherapy are well-studied, scientific evidence on the impact of charged particle therapy on cancer cell radioresistance is restricted. The purpose of this review is to discuss the potential role that charged particles could play to overcome radioresistance. This review will focus on hypoxia, cancer stem cells, and specific signaling pathways of EGFR, NFκB, and Hedgehog as well as DNA damage signaling involving PARP, as mechanisms of radioresistance for which pharmacological targets have been identified. Finally, new lines of future research will be proposed, with a focus on novel molecular inhibitors that could be used in combination with charged particle therapy as a novel treatment option for radioresistant tumors. Frontiers Media S.A. 2020-02-14 /pmc/articles/PMC7033551/ /pubmed/32117774 http://dx.doi.org/10.3389/fonc.2020.00128 Text en Copyright © 2020 Konings, Vandevoorde, Baselet, Baatout and Moreels. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Konings, Katrien
Vandevoorde, Charlot
Baselet, Bjorn
Baatout, Sarah
Moreels, Marjan
Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance
title Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance
title_full Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance
title_fullStr Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance
title_full_unstemmed Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance
title_short Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance
title_sort combination therapy with charged particles and molecular targeting: a promising avenue to overcome radioresistance
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033551/
https://www.ncbi.nlm.nih.gov/pubmed/32117774
http://dx.doi.org/10.3389/fonc.2020.00128
work_keys_str_mv AT koningskatrien combinationtherapywithchargedparticlesandmoleculartargetingapromisingavenuetoovercomeradioresistance
AT vandevoordecharlot combinationtherapywithchargedparticlesandmoleculartargetingapromisingavenuetoovercomeradioresistance
AT baseletbjorn combinationtherapywithchargedparticlesandmoleculartargetingapromisingavenuetoovercomeradioresistance
AT baatoutsarah combinationtherapywithchargedparticlesandmoleculartargetingapromisingavenuetoovercomeradioresistance
AT moreelsmarjan combinationtherapywithchargedparticlesandmoleculartargetingapromisingavenuetoovercomeradioresistance